NCT07746349Not yet recruiting
Terlipressin vs Placebo to Reduce Bleeding in Fibroid Surgery
Efficacy of Subcapsular Diluted Terlipressin Versus Placebo in Reducing Intraoperative Blood Loss During Myomectomy: A Randomized, Double-Blind, Placebo-Controlled Trial
Source: ClinicalTrials.gov · Last updated 5 Aug 2026
Brief summary (registry, in English)
A myomectomy is a surgery to remove noncancerous growths (fibroids) from the uterus while keeping the uterus in place. This surgery can cause significant blood loss. Terlipressin is a medicine that narrows blood vessels and may help reduce bleeding. This study will test whether injecting a diluted terlipressin solution under the outer covering of the fibroid, before it is removed, reduces the amount of blood lost during surgery, compared to an inactive solution (placebo). Women scheduled for myomectomy will be randomly assigned to receive either terlipressin or placebo. Neither the patients nor the surgical team will know which one was given until the study is finished. The main question this study will answer is how much blood is lost during surgery in each group.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 24 Jul 2026
- Start date
- 1 Aug 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- Sevil Cankaya
- NCT number
- NCT07746349
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 1 Aug 2026 to the primary completion date, Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current anticoagulant or antiplatelet therapy
- Previous myomectomy
- Concurrent pelvic pathology requiring additional surgical intervention
- Treatment with a GnRH agonist or ulipristal acetate within the 3 months preceding surgery
Other illness
- History of bleeding disorders or coagulopathy
- Known hypersensitivity or contraindication to terlipressin
- Uncontrolled hypertension
- Severe cardiac arrhythmia
- Uncontrolled ischemic heart disease
- Peripheral vascular disease
- Suspected uterine malignancy, such as leiomyosarcoma
Other
- Pregnancy or suspected pregnancy
- Inability to understand or provide informed consent
Who the study is looking for
- Symptomatic uterine fibroid(s) with an indication for myomectomy, including menorrhagia, pelvic pain/pressure, or infertility
- Largest myoma diameter between 4 and 10 cm
- Baseline hemoglobin ≥ 9 g/dL
- Not pregnant at the time of enrollment
- Negative urine pregnancy test or last menstrual period within 4 weeks
- Willing and able to provide written informed consent
Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.